In summary, these data indicate that the glucose-lowering effect of sacubitril/valsartan, as evidenced by a small but significant reduction in HbA1c and new use of insulin, was similar in heart failure patients with diabetes across the spectrum of LVEF. The gene discussed is INS; the disease is heart failure.